WallStreetZenWallStreetZen

NASDAQ: VNDA
Vanda Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

VNDA past earnings growth

How has VNDA's earnings growth performed historically?
Company
-63.64%
Industry
52.11%
Market
105.88%
VNDA's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
VNDA's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
VNDA's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

VNDA past revenue growth

How has VNDA's revenue growth performed historically?
Company
-24.27%
Industry
149.3%
Market
17.29%
VNDA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VNDA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VNDA's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VNDA earnings and revenue history

Current Revenue
$192.6M
Current Earnings
$2.5M
Current Profit Margin
1.3%

VNDA Return on Equity

Current Company
0.5%
Current Industry
-63.5%
Current Market
188%
VNDA's Return on Equity (0.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VNDA announces earnings.

VNDA Return on Assets

Current Company
0.4%
Current Industry
2.9%
VNDA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VNDA Return on Capital Employed

Current Company
1.13%
Current Industry
19.5%
VNDA's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VNDA vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VNDA$192.64M$9.35M$2.51M-0.05%-39.66%
GLUE$0.00-$128.79M-$135.35MN/AN/A
IMMP$4.40MN/A-$26.47M+4.12%N/A
RAPT$0.00-$113.25M-$116.80M-100.00%N/A
ERAS$0.00-$121.31M-$125.04MN/AN/A
View Top Biotech Stocks

VNDA earnings dates

Next earnings date
May 1, 2024

Vanda Pharmaceuticals Earnings & Revenue FAQ

What were VNDA's earnings last quarter?

On Invalid Date, Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 2023 earnings per share (EPS) of -$0.05, up 141.67% year over year. Total Vanda Pharmaceuticals earnings for the quarter were -$2.40 million. In the same quarter last year, Vanda Pharmaceuticals's earnings per share (EPS) was $0.12.

If you're new to stock investing, here's how to buy Vanda Pharmaceuticals stock.

What was VNDA's earnings growth in the past year?

As of Q2 2024, Vanda Pharmaceuticals's earnings has grown -63.64% year over year. This is 115.75 percentage points lower than the US Biotechnology industry earnings growth rate of 52.11%. Vanda Pharmaceuticals's earnings in the past year totalled $2.51 million.

What is VNDA's earnings date?

Vanda Pharmaceuticals's earnings date is Invalid Date. Add VNDA to your watchlist to be reminded of VNDA's next earnings announcement.

What was VNDA's revenue last quarter?

On Invalid Date, Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 2023 revenue of $45.27 million up 29.79% year over year. In the same quarter last year, Vanda Pharmaceuticals's revenue was $64.48 million.

What was VNDA's revenue growth in the past year?

As of Q2 2024, Vanda Pharmaceuticals's revenue has grown -24.27% year over year. This is 173.57 percentage points lower than the US Biotechnology industry revenue growth rate of 149.3%. Vanda Pharmaceuticals's revenue in the past year totalled $192.64 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.